Houte Hans Van Sells 5,825 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. This represents a 14.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Houte Hans Van also recently made the following trade(s):

• On Thursday, January 30th, Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock. The shares were sold at an average price of $19.85, for a total value of $55,798.35.

Nurix Therapeutics Trading Up 0.5 %

NRIX opened at $14.26 on Wednesday. The firm has a market cap of $1.08 billion, a P/E ratio of -4.93 and a beta of 2.14. Nurix Therapeutics, Inc. has a 12 month low of $11.90 and a 12 month high of $29.56. The stock has a 50-day moving average of $18.40 and a 200 day moving average of $21.72.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NRIX. FMR LLC boosted its position in shares of Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company’s stock valued at $200,349,000 after buying an additional 10,047,329 shares during the period. RA Capital Management L.P. purchased a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $25,120,000. Soleus Capital Management L.P. boosted its position in shares of Nurix Therapeutics by 97.3% during the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock valued at $39,617,000 after buying an additional 1,036,999 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $16,447,000. Finally, Boxer Capital Management LLC purchased a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $10,608,000.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NRIX shares. Royal Bank of Canada raised their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Needham & Company LLC cut their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Stifel Nicolaus raised their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. BMO Capital Markets started coverage on Nurix Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, Stephens restated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $31.81.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.